Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668772 · ClinicalTrials.gov registry record · Phase 3
Tiotropium/Salmeterol Inhalation Powder in COPD
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 3
- Development phase
- 207
- Enrollment target
NCT00668772: Clinical Trial Phase 3 study, sponsored by Boehringer Ingelheim.
NCT00668772 is a Phase 3 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 207 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00668772, a Phase 3 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 207 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined bt the SGRQ and the effect on COPD exacerbations
Primary Outcome
Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the
Interventions
- DRUG Placebo
- DRUG Tiotropium
- DRUG Salmeterol
- DRUG Tiotropium/Salmeterol
- DRUG Tiotropium/Salmeterol QD + Salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2008-04-15 |
| Est. Completion | 2008-11-21 |
| Phase | Phase 3 |
Why NCT00668772 stopped before completion
NCT00668772 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00668772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00668772 about?
NCT00668772 is a clinical study titled "Tiotropium/Salmeterol Inhalation Powder in COPD". The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined bt the SGRQ and the effect on COPD exacerbations
What is the current status of trial NCT00668772?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 207 participants. The study started on 2008-04-15. Estimated completion is 2008-11-21.
What interventions are being tested in trial NCT00668772?
The interventions under investigation include: Placebo (DRUG), Tiotropium (DRUG), Salmeterol (DRUG), Tiotropium/Salmeterol (DRUG), Tiotropium/Salmeterol QD + Salmeterol (DRUG).
Who is sponsoring clinical trial NCT00668772?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00668772's enrollment target sits among peer trials
207 1346th of 2000 higher than 654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI